We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

126 hedge funds and large institutions have $249M invested in CytomX Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.45% more ownership

Funds ownership: 79.76% → 82.21% (+2.4%)

2% more capital invested

Capital invested by funds: $243M → $249M (+$5.62M)

3% less funds holding

Funds holding: 130 → 126 (-4)

16% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 51

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
126
Holders Change
-4
Holders Change %
-3.08%
% of All Funds
2.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
43
Reduced
51
Closed
15
Calls
$88K
Puts
–
Net Calls
+$88K
Net Calls Change
+$22K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$14.4M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$2.46M
3
Morgan Stanley
Morgan Stanley
New York
+$2.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.58M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$2.3M
2
BlackRock
BlackRock
New York
-$2.15M
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$1.85M
4
Norges Bank
Norges Bank
Norway
-$1.76M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$36.5M +$14.4M +2,016,749 +57%
BlackRock
2
BlackRock
New York
$24.9M -$2.15M -301,548 -7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$19.2M +$573K +80,236 +3%
PA
4
Perceptive Advisors
New York
$16.9M – – –
Victory Capital Management
5
Victory Capital Management
Texas
$15.2M -$789K -110,409 -5%
Renaissance Technologies
6
Renaissance Technologies
New York
$13.5M -$1.72M -240,100 -10%
State Street
7
State Street
Massachusetts
$13.4M -$705K -98,657 -5%
RI
8
RTW Investments
New York
$10M +$9.64K +1,349 +0.1%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$6.85M +$1.58M +220,700 +27%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$4.97M +$36.8K +5,150 +0.7%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$4.54M +$992K +138,800 +25%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$4.51M +$755K +105,675 +18%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$4.5M -$1.43K -200 -0%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$4.04M +$739K +103,511 +20%
N
15
Nuveen
North Carolina
$4M -$147K -20,523 -3%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$3.96M -$75K -10,502 -2%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$3.63M -$119K -16,700 -3%
Northern Trust
18
Northern Trust
Illinois
$3.44M -$41.7K -5,833 -1%
Two Sigma Investments
19
Two Sigma Investments
New York
$3.37M +$646K +90,419 +21%
Millennium Management
20
Millennium Management
New York
$2.38M +$472K +66,047 +22%
Federated Hermes
21
Federated Hermes
Pennsylvania
$2.38M +$2.46M +344,186 +1,863%
Charles Schwab
22
Charles Schwab
California
$2.32M +$224K +31,401 +10%
PIM
23
Platinum Investment Management
Australia
$1.99M +$738K +103,241 +52%
Morgan Stanley
24
Morgan Stanley
New York
$1.98M +$2.1M +293,828 +3,762%
Arrowstreet Capital
25
Arrowstreet Capital
Massachusetts
$1.87M +$1.26M +175,693 +159%
1
2 3 4 5

CTMX Hedge Fund Activity: Q4 2020 in Review

126 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2020, worth a combined $249M — up 2.3% from $243M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CTMX and 11 opened new positions — a net loss of 4 holders — while 51 trimmed existing stakes and 43 added.

The largest buyer was BVF Inc, adding an estimated $14.4M. The largest seller was First Manhattan, exiting entirely with an estimated $2.3M sold.

  • 126 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2020, down from 130 in Q3 2020.
  • Funds reported $249M of CytomX Therapeutics stock for Q4 2020, up 2.3% quarter-over-quarter.
  • 11 funds opened new CytomX Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
  • The largest CytomX Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14.4M added.
  • The largest CytomX Therapeutics seller in Q4 2020 was First Manhattan, an estimated $2.3M sold.

Based on aggregated 13F filings for Q4 2020.